Sanjay Chanda - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Development Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol
ANTX
Transactions as of
24 Mar 2022
Net transactions value
$0
Form type
3
Filing time
24 Mar 2022, 21:19:04 UTC
Next filing
16 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 80,472 $0.4200 Direct F1
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 19,444 $0.4200 Direct F2
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 41,665 $6.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on May 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
F2 The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from October 5, 2020, subject to the Reporting Person's continuous service as of such date.
F3 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.

Remarks:

Exhibit 24 - Power of Attorney